Know Cancer

forgot password

"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Phase 3
18 Years
75 Years
Not Enrolling
Advanced Unresectable Pancreatic Cancer

Thank you

Trial Information

"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

The trial is a Phase III, multinational, multicentre, controlled, randomised open-label
trial. It will involve 520 advanced pancreatic cancer patients. Patients will be randomly
assigned to receive Gemcitabine alone or GV1001 plus GM-CSF followed by addition of
Gemcitabine at the time of 1st progression of disease. The experimental treatment is given
prior to the current standard treatment in 50% of the patients.

Inclusion Criteria:

1. Histologically or cytologically confirmed, unresectable, locally advanced, or
metastatic adenocarcinoma of the pancreas.

2. Adequate hematological parameters:

Hemoglobin >/= 9.5 g/dL [SI units, 5.9 mmol/L] WBC >/= 3000/mm3 [SI units, >/= 3 x
109/L] Platelets >/= 100,000/mm3 [SI units, >/= 100 x 109/L]

3. Adequate baseline liver function:

Total Bilirubin < 3x ULN and

Without liver metastases:

With liver metastases:

4. Serum creatinine
5. Performance status ECOG 0-1.

6. Male or female 18 - 75 years inclusive.

7. Minimum life expectancy of 3 months.

8. Written informed consent.

Exclusion Criteria:

1. Treatment with chemotherapy for pancreatic cancer.

2. Treatment with other investigational drugs within the last 4 weeks prior to inclusion

3. Immune-suppressive therapy <4 weeks prior to inclusion

4. Chronic corticosteroid use except for asthma inhalers / topical use

5. Radiotherapy within 8 weeks of randomisation.

6. Other prior malignancies except for adequately treated non-melanoma skin cancers
(BCC, SCC) and carcinoma in situ of the cervix.

7. Known diagnosis of HIV (AIDS), Hepatitis B, C.

8. Known history of or co-existing autoimmune disease.

9. Known CNS metastases.

10. Clinically significant serious disease or organ system disease not currently
controlled on present therapy.

11. Pregnancy or lactation.

12. Women of childbearing potential not using reliable and adequate contraceptive

13. Known sensitivity to any components of vaccine, gemcitabine or GM-CSF.

14. Unable for any other reason to comply with the protocol (treatment or assessments).

- Adequate contraceptive methods are defined as the use of oral, implanted,
injectable, mechanical or barrier products for the prevention of pregnancy; or
women who are practising abstinence; or where the partner is sterile, for
example a vasectomy.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall survival time

Outcome Time Frame:

12 month

Safety Issue:


Principal Investigator

Ask Aabenhus, MSc. (Pharm)

Investigator Role:

Study Director

Investigator Affiliation:

Pharmexa A/S


France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:




Start Date:

June 2006

Completion Date:

August 2008

Related Keywords:

  • Advanced Unresectable Pancreatic Cancer
  • Advanced
  • Unresesctable
  • Adenocarcinoma
  • Pancreatic cancer
  • Pancreatic Neoplasms



Southwest Regional Cancer Center Austin, Texas  78705
University of South Alabama Mitchell Cancer Institute Mobile, Alabama  36604
Palm Beach Cancer Institute West Palm Beach, Florida  33401
Genesis Cancer Center Hot Springs, Arkansas  71913
Gabrail Cancer Center Canton, Ohio  44718
Oncology Hematology Associates of Central Illinois, PC Peoria, Illinois  61602
The Center for Hematology-Oncology Boca Raton, Florida  33486
Desert Hematology Oncology Medical Group, Inc. Rancho Mirage, California  92270
Billings Clinic Billings, Montana  59107-7000
Scripps Clinic Torrey Pines La Jolla, California  92037
Tampa General Hospital Usf Digestive Disorders Centre Tampa, Florida  33606
Portneuf Cancer Center Pocatello, Idaho  83204
Hematology Oncology Specialists, Covington Covington, Louisiana  70433
Berskhire Hematology Oncology PC Pittsfield, Massachusetts  01201
Carolinas Hematology Oncology Associates Charlotte, North Carolina  28203
Toledo Community Hospital Oncology Program Toledo, Ohio  43617
Mary Crowley Medical Research Center, Worth St. Dallas, Texas  75249
Mary Crowley Medical Research Center (MCMRC)Texas Oncology-Presbyrerian Hospital of Dallas Dallas, Texas  75231
Oncology Consultants, PA Houston, Texas  77024